Victoza

  • Email
  • Help

Questions & Answers

On 22 June 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Victoza. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S.

The CHMP adopted a change to the existing indication. The indication will read as follows1:

"Victoza is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to achieve glycaemic control  as an adjunct to diet and exercise:

  • as Mmonotherapy When diet and exercise alone do not provide adequate glycaemic control in patients for whom use ofwhen metformin is considered inappropriate due to intolerance or contraindications.

Combination therapy

In combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4 and 5.1 for available data on the different combinations).

•in addition to other medicinal products for the treatment of diabetes.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1."

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1New text in bold, removed text as strikethrough

Name Language First published Last updated
CHMP post-authorisation summary of positive opinion for Victoza (II-42) (English only) 2017-06-23  

Key facts

Product details for Victoza
NameVictoza
INN or common name

liraglutide

Therapeutic area Diabetes Mellitus, Type 2
Active substance

liraglutide

Date opinion adopted22/06/2017
Company name

Novo Nordisk A/S

StatusPositive
Application typePost authorisation